Poseida Therapeutics — Investor Day (April 2024)
87 slides from Poseida Therapeutics's investor day presentation, Apr 17, 2024
Slide 1: Gene Therapy R&D Day
Exhibit 99.2 Gene Therapy R&D Day Advancing next -generation non -viral genetic medicines with the capacity to cure th APRIL 17 , 2024
Slide 2: Disclaimer
Disclaimer This presentation and any accompanying oral commentary contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts and include, without limitation, statem
Slide 3: Welcome & Introduction
Welcome & Introduction P r e s e n t e r : K r i s t i n Ya r e m a , P h D
Slide 4: Agenda
Agenda Introduction Kristin Yarema, PhD P-KLKB1-101 Program / Platform Marc Riedl, MD, MS / Blair Madison, PhD / Bonnie Jacques, PhD Non-viral system Jack Rychak, PhD P-FVIII-101 Program / Platform Steven Pipe, MD / Blair Madison, PhD Site specific SPB Blair Madison, PhD Conclusion Kristin Yarema, P
Slide 5: On a mission to advance a new class of cell therapies & genetic medicines
On a mission to advance a new class of cell therapies & genetic medicines designed to cure ALLOGENEIC CAR-T GENETIC MEDICINES The future of cell therapy Non-viral delivery of genetic is allo editing and gene therapies to enable access for all patients OUR PEOPLE OUR PLATFORMS Passionate and dedicate
Slide 6: Early technologies for genetic medicines have presented many challenges
Early technologies for genetic medicines have presented many challenges Manufacture and delivery Gene replacement Gene modification AAV TALEN AAV manufacture Lentivirus Zinc Fingers Conventional lipids Other viral vectors Cas9 mRNA therapy BE/PE ─ Low fidelity, low activity, or low ─ AAV (high-cost
Slide 7: Peter Marks quote on non-viral vectors for gene therapy
“We are enthusiastic to see the development of non- viral vectors for gene therapy and look forward to working with sponsors on these programs as they work to achieve the necessary efficiency needed for effective gene transfer.” – Peter Marks, Director of the Center for Biologics Evaluation and Rese
Slide 8: Poseida's vision for genetic medicine
Poseida’s vision for genetic medicine Effective – capacity to cure* Safe – non-viral, low immunogenicity lipid nanoparticles Durable – stable genome editing/insertion Provide patients with corrective, transformational therapeutic benefit through Patient-friendly – single or short course of treatment
Slide 9: This product vision requires an entirely new suite of technologies
This product vision requires an entirely new suite of technologies Manufacture and delivery Whole gene insertion High fidelity gene editing RNA-guided DNA nuclease LNP DNA transposon ✓ Integrated, stable expression✓ Exceptional fidelity ✓ Low immunogenicity ✓ Large cargo capacity for whole genes✓ Ef
Slide 10: Versatility in developing products tailored to therapeutic need
Versatility in developing products tailored to therapeutic need Potential to add proprietary innovation elements onto core technology components Core technology suite Product candidate Optimized High-fidelity Proprietary ± a ± a insertion editing lipid library Innovation elements Safety Activity Opt
Slide 11: Launching into in vivo gene editing and insertion
Launching into in vivo gene editing and insertion, building upon ex vivo expertise Deploying our genetic engineering technologies to address serious diseases Gene editing Gene insertion P-KLKB1-101: P-FVIII-101: Non-viral whole gene insertion In vivo Non-viral Cas-CLOVER Focus for for functional cor
Slide 12: Advancing forward with our proprietary non-viral systems with strategic focus
Advancing forward with our proprietary non-viral systems with strategic focus Building from foundational learnings to advance a highly differentiated approach across gene and cell therapy Validation of Cas- Adopted fully non-viral Deploy non-viral Developed hybrid CLOVER non-viral AAV+LNP platform i
Slide 13: Focused development of key programs within areas of significant opportunity
Focused development of key programs within areas of significant opportunity P-FVIII-101: Hemophilia A P-KLKB1-101: Hereditary Angioedema RESEARCH PRECLINICAL IND-ENABLING RESEARCH PRECLINICAL IND-ENABLING Non-viral Cas-CLOVER Non-viral whole gene editing of disease- insertion for functional relevant
Slide 14: Guest speakers
Guest speakers Marc Riedl, MD, MS Professor of Medicine at University of California, San Diego Steven W. Pipe, MD Professor of Pediatrics and Pathology, University of Michigan 14 © © 2024 2024 Po Pos se eid ida a T Th he era rap pe eu utics tics, , In Inc. c. All All Rig Righ hts ts Res Rese erv rve
Slide 15: Hereditary Angioedema (HAE): Where Are We Now?
Hereditary Angioedema (HAE): Where Are We Now? Marc Riedl MD, MS Professor of Medicine at University of California, San Diego
Slide 16: HAE Clinical Features
HAE Clinical Features Angioedema without urticaria: Severe and unpredictable • Affected areas: Face, oropharynx, extremities, GI, genitourinary tract ‒ Risk of death by asphyxiation ‒ Prolonged attacks, intensifying over 24 hours, lasting 2-4 days • Unresponsiveness to traditional therapies: antihis
Slide 17: Incidence and anatomical location of HAE Symptoms
Incidence and anatomical location of HAE Symptoms * 250 Per-patient Analysis Longitudinal assessment • 221 patients with HAE 100% 97% 200 • 5736 patient-years of observation 150 • 131,110 angioedema episodes 54% 100 • 1,229 laryngeal edema episodes; impacted 108 of 209 22% 50 9% patients (51.7%) 8%
Slide 18: HAE pathophysiology
HAE pathophysiology Trace FXIIa or Trace activity in native FXII Prekallikrein (KLKB1 gene) Surface HMW Kininogen FXIIa FXII HMW Kininogen Kallikrein HMW Kininogen Increased vascular permeability and Bradykinin angioedema FXIIa FXII FXIIf Surface = Inhibited by C1-INH Autodigestion Kallikrein C4 & C
Slide 19: History of HAE therapies
History of HAE therapies • C1-INH replacement therapy st Common Mechanisms of Action in 21 century: • Kallikrein inhibition (from KLKB1 gene) • Bradykinin B2 receptor antagonism 2017 2009 2011 2014 2020 2018 1985 1960 1969 1972 1976 1979 FDA Approval Years 19
Slide 20: Current treatment strategies for HAE
Current treatment strategies for HAE Required for Used as needed for HAE-C1INH ALL patients individual patients Short-term Long-term On-demand prophylaxis prophylaxis To rapidly stop an To prevent an attack To decrease the existing attack before when the patient will frequency and the patient be exp
Slide 21: Impact of HAE on patient lives
Impact of HAE on patient lives Early onset Delayed diagnosis Misdiagnosis Acute/chronic Disease Chronic treatment Course ED visits Unpredictable Hospitalization Prolonged Frequency Direct medical Disfiguring Nature Indirect Costs Painful Burden of Attacks Debilitating Life threatening of HAE Work/sc
Slide 22: Consensus on treatment goals in HAE
Consensus on treatment goals in HAE • Global Delphi Initiative: Panel of 23 international HAE experts Unanswered Questions for – Consensus agreement of >75% Future HAE therapies: • Safety • Key Ultimate Goals – Normalize the patient’s life (100%) • Efficacy – Achieve total control of the disease (95
Slide 23: The road forward for unmet needs
The road forward for unmet needs • Current state of patient management: – Prevention of death and excessive pain – Reduced hospitalizations and disability • Unmet Needs: – Reduced treatment burden and frequency – Life without interference from HAE • Potential Next-Generation Therapies – KLKB1-target
Slide 24: Thank you
Thank you
Slide 25: P-KLKB1-101 for the treatment of Hereditary Angioedema (HAE)
P-KLKB1-101 for the treatment of Hereditary Angioedema (HAE) Ap p lication of Cas - CLOV ER P r e s e n t e r : B l a i r M a d i s o n , P h D
Slide 26: HAE patients have an unmet need for a safe therapy with durable efficacy
HAE patients have an unmet need for a safe therapy with durable efficacy P-KLKB1-101: Potential technology advantages Safety Durability ✓ Sustained efficacy via KLKB1/kallikrein ✓ High fidelity editing of KLKB1 gene using Cas- inactivation for long-term relief CLOVER ✓ Relief from treatment burden a
Slide 27: Our gene editing approach to durable correction for hereditary angioedema
Our gene editing approach to durable correction for hereditary angioedema Hereditary angioedema (HAE) HAE treated with P-KLKB1-101 C1-INH Cas-CLOVER nuclease Factor XIIa Factor XIIa L-sgRNA Prekallikrein Kallikrein Prekallikrein Kallikrein KLKB1 R-sgRNA Bradykinin HMW Kininogen HMW Kininogen Bradyki
Slide 28: Cas-CLOVER provides clean gene editing: engineered for high specificity
Cas-CLOVER provides clean gene editing: engineered for high specificity High-fidelity Poseida system via a dual guide RNA approach for a highly specific “molecular address” Cas-CLOVER dimerized editor Traditional CRISPR products single gRNA obligate reduces 2 1 dual gRNA = dimerization specificity s
Slide 29: Cas-CLOVER gene editing system yields 20x higher fidelity than Cas9
Cas-CLOVER gene editing system yields 20x higher fidelity than Cas9 Differentiated system with low to no off-target editing across multiple cells/targets The difference On-Target Editing Off-Target Editing 20 20x Cas-CLOVER technology: 100 15 • 20x higher fidelity than Cas9 nuclease 75 • High on-tar
Slide 30: Unrivaled high fidelity at KLKB1 locus, yielding <0.1% off-target editing
Unrivaled high fidelity at KLKB1 locus, yielding <0.1% off-target editing KLKB1 off-target evaluation in liver (primary human hepatocytes) in the context of 90% on-target editing Cas-CLOVER off-target editing: KLKB1 gRNA pair On-target 95 95 (KLKB1) 85 85 1.0 1.0 0.9 0.8 0.7 0.6 0.5 0.5 0.4 0.3 0.2
Slide 31: Cas-CLOVER maintains high fidelity even at 75x dose escalation
Cas-CLOVER maintains high fidelity even at 75x dose escalation Cas-CLOVER editing in primary human hepatocytes Off-target editing rate 100 80 >15x On-target 60 EC50 40 20 5 4 3 OT1, 2, 3: validated 2 off-target site 1 0 • Cas9 yields compromised fidelity at higher doses • No escalated off-target edi
Slide 32: In vivo application of Cas-CLOVER: Pharmacology studies
P-KLKB1-101 for the treatment of Hereditary Angioedema (HAE) In vivo ap p lication of Cas - CLOV ER: Ph armacology stu dies P r e s e n t e r : B o n n i e J a c q u e s , P h D
Slide 33: Stable targeted reduction of HAE biomarker with KLKB1 gene editing
Stable targeted reduction of HAE biomarker with KLKB1 gene editing Dose-responsive reduction with candidate LNP exceeds performance target in mice Poseida ionizable lipid Enhanced Plasma kallikrein reduction Cas-CLOVER mRNA KLKB1-specific 150 gRNA pair Relative Dose PBS Low 100 Med. High Lead LNP ca
Slide 34: Wide effective dose range provides opportunity for titrating doses
Wide effective dose range provides opportunity for titrating doses Candidate yields controlled dose-dependent reduction in targeted kallikrein protein Liver KLKB1 editing Plasma kallikrein levels Editing vs. kallikrein levels 125 125 80 PBS Minimal 0.5x 100 100 Effective Dose 1x 60 1.5x 75 75 2.5x 5
Slide 35: Favorable safety and tolerability supports a wide therapeutic index
Liver Lipid Level (ug/g) Favorable safety and tolerability supports a wide therapeutic index Rapid lipid clearance with no acute liver toxicity concerns Liver lipid clearance 150 250 • Rapid clearance of Poseida ionizable lipid 200 100 ─ Key for minimizing liver toxicity 150 MC3 100 • 7x faster than
Slide 36: Validation across multiple species, progress towards clinical readiness
Validation across multiple species, progress towards clinical readiness • Thought-leader engagement Clinical • Assessing clinical sites and protocols • Process dev completed• Manufacturing (Tox & GMP) CMC scheduled and ongoing • Analytical dev progressing Regulatory • Successful initial interaction
Slide 37: Poseida's non-viral gene insertion system
Poseida’s non-viral gene insertion system P r e s e n t e r : J a c k Ry c h a k , P h D
Slide 38: Transformative genetic medicines require sophisticated delivery and insertion technologies
Transformative genetic medicines require sophisticated delivery and insertion technologies Our solution Optimal system can both insert sizeable DNA cargo and deliver it via a safe, non-viral approach such as The problem: engineered nanoparticles • Loss of gene function underpins many addressable gen
Slide 39: Efficient large DNA delivery unlocks the potential of genetic medicines
N N N U U U C C C Efficient large DNA delivery unlocks the potential of genetic medicines Poseida approach entails insertion of whole-gene DNA cargo for universal correction Patient 1 Functional gene Patient 2 Cell function restored Patient 3 Single drug product Same disease caused by different muta
Slide 40: Poseida molecular platform enables cut-and-paste insertion of large DNA cargo
Poseida molecular platform enables cut-and-paste insertion of large DNA cargo Super piggyBac (SPB) is a high-efficiency transposon system for inserting genes into the genome SPB gene insertion platform Why SPB? DNA Cargo SPB Transposase • Unique product versatility Containing corrective gene sequenc
Slide 41: Our non-viral delivery technology is poised to unlock the field of genetic medicine
Our non-viral delivery technology is poised to unlock the field of genetic medicine Why non-viral? Nanoparticle drug product Delivery of gene-size DNA Corrective • Nanoparticle cargo capacity enables delivery of gene (DNA) SPB transposase full genes to address all patient mutations (mRNA) Safety / E
Slide 42: Conventional mRNA-LNP platforms are not suitable for DNA delivery
Conventional mRNA-LNP platforms are not suitable for DNA delivery LNP provides a strong foundation upon which to build a non-viral DNA delivery system Safety challenge Efficiency barrier Serum IL-6 mRNA-LNP DNA-LNP >90% < 1% Broad expression Infrequent expression across liver Immunocompetent adult m
Slide 43: Poseida non-viral technology goes beyond the conventional lipid nanoparticle
Poseida non-viral technology goes beyond the conventional lipid nanoparticle Incorporates the best of our proprietary technologies to enable powerful product candidates Core technology suite Product candidate Optimized High-fidelity Proprietary ± a ± a insertion editing lipid library Innovation elem
Slide 44: Designed to enable the clean delivery of DNA
Designed to enable the clean delivery of DNA Hepato-safety for FVIII DNA Delivery • Unintended immune cell uptake leads to release 6000 of pro-inflammatory cytokines 5000 ─ Can result in cell dysfunction and death 4000 • Platform de-targets immune cells and armors 3000 hepatocytes from pro-inflammat
Slide 45: Engineered for efficient hepatocyte transduction
Engineered for efficient hepatocyte transduction Significant increase in DNA activity with ICTA • Poseida-invented ionizable lipids exhibit unique DNA-LNP functionality for packaging large DNA molecules + ICTA DNA-LNP • Targeting construct enables active targeting of 1.8E10 p/s/cm2/sr 1.6E8 p/s/cm2/
Slide 46: Exponential enhancement of secreted transgene expression for max efficacy
Exponential enhancement of secreted transgene expression for max efficacy Serum hFVIII protein expression >500-fold enhancement 1000 100 (therapeutic target) 10 Poseida non-viral system 1 0.1 Conventional LNP-A LN vP 1- B v2 LNP -1 v3 LNP-2 DNA-LNP Poseida non-viral Poseida-proprietary ICTA Targetin
Slide 47: Significant increase in hepatocyte transduction with cell trafficking agent
Significant increase in hepatocyte transduction with cell trafficking agent Progression toward non-viral treatment of metabolic diseases C12 – SPB PCCA (propionic acidemia) Arginase Deficiency Phenylketonuria Conventional DNA-LNP (ARG1) (PAH) 100 Poseida LNP Poseida LNP 50 30X Poseida LNP 0 Juvenile
Slide 48: Poseida's non-viral platform achieving AAV efficiency
DAPI (blue), PAH (red) Poseida’s non-viral platform achieving AAV efficiency + AAV + mRNA-LNP Non-viral platform Juvenile immunocompetent mice co-administered AAV-PAH donor and mRNA–LNP (left) or administered single dose of Poseida LNP (right) intravenously; immunostaining for PAH protein. 48 © 2024
Slide 49: Poseida's non-viral transposon technology uniquely addresses needs of an optimal product
Poseida’s non-viral transposon technology uniquely addresses needs of an optimal product Gene editing and insertion technologies Gene delivery technologies Nuclease Non-viral Base/prime (knock-in) editor transposon • Delivery technologies that Single product coverage are non-integrating, (AAV, (abil
Slide 50: Poised for the next wave of non-viral gene therapies
Poised for the next wave of non-viral gene therapies Summary • Non-viral delivery of gene-size DNA may enable treatment of broad patient populations safely and cost-effectively • DNA is a difficult payload to deliver due to transduction challenges and unique immune-safety hurdles • Builds on convent
Slide 51: Treatment landscape for Hemophilia A: Available Therapies and Unmet Needs
Treatment landscape for Hemophilia A: Available Therapies and Unmet Needs Steven W. Pipe, MD Professor of Pediatrics and Pathology, University of Michigan © 2024 Poseida Therapeutics, Inc. All Rights Reserved.
Slide 52: Clinical classification of Hemophilia
Clinical classification of Hemophilia 30,000-33,000 persons with Hemophilia in the USA • 85% with Hemophilia A (factor VIII deficiency) • 15% with Hemophilia B (factor IX deficiency) Severe Moderate Mild Classification (40%- 50%) (10%) (30%- 40%) FVIII or FIX activity <1% 1%–5% 6%–30% Pattern of ble
Slide 53: A single hemarthrosis can result in joint disease later in life
A single hemarthrosis (joint bleed) can result in joint disease later in life 1 The risk of joint damage increases with each subsequent hemarthrosis The hemarthrosis-synovitis-hemarthrosis vicious circle in 2 hemophilia • Musculoskeletal bleeding episodes, Clinical manifestations including hemarthro
Slide 54: Treatment for Hemophilia A is evolving
Treatment for Hemophilia A is evolving 1 Gene therapy and 4 additional factor and Recombinant 5 nonfactor therapies FVIII products Main treatment options used today: are under clinical 2 improved safety; investigation • Factor replacement therapy EHL products and a nonfactor therapy Factor VIII • Bi
Slide 55: Current prophylaxis regimens are inadequate to safeguard individuals with Hemophilia
Current prophylaxis regimens are inadequate to safeguard individuals with Hemophilia • Unmet need for hemophilia patients requiring treatments that improve Quality of Life • Factor replacement disadvantageous for QoL due to treatment peaks/troughs and lack of constant FVIII levels over time 1, 2, 3
Slide 56: Despite many advances, unmet needs in Hemophilia remain
Despite many advances, unmet needs in Hemophilia remain Unmet needs Expectations for better care Prophylaxis for all patients with relevant bleeding 1,2 Barriers to adoption of prophylaxis phenotype 3 Poor adherence to prophylactic regimens Improve adherence to treatment Zero bleeds, particularly jo
Slide 57: Current and future approaches to care for Hemophilia A
Current and future approaches to care for Hemophilia A Pre-replacement Replacement Non-replacement 1–3 Viral Gene Therapy Future Therapy 1,2 1–3 Therapy Therapy Therapy Mimetics / agonists rAAV vector-mediated Non-viral technologies On demand Prophylaxis Substitution therapy Liver-directed Liver-dir
Slide 58: Goals and risks of gene therapy in Hemophilia
Goals and risks of gene therapy in Hemophilia Potential safety issues for all gene therapies in Reduce ABR Reduce development for hemophilia anxiety Liver toxicity Transaminitis, liver toxicity Increase Impaired immunity Factor Immunosuppressive therapy often required Reduce Levels burden Reduce Thr
Slide 59: Potential pros and cons of current gene therapy for Hemophilia
Potential pros and cons of current gene therapy for Hemophilia Viral Gene Therapy Ideal Pros Cons Pediatric to adult patients Individualized titration Some patients currently ineligible Single-infusion event Repeat administration (children, NAb, factor inhibitors) Liberation from prophylaxis burden
Slide 60: Thank you
Thank you
Slide 61: P-FVIII-101 for the treatment of Hemophilia A
P-FVIII-101 for the treatment of Hemophilia A In vivo ap p lication o f n o n -viral syste m P r e s e n t e r : B l a i r M a d i s o n , P h D
Slide 62: Key challenges for AAV and episomal approaches to Hemophilia A
Key challenges for AAV and episomal approaches to Hemophilia A Poseida non-viral Desirable feature Episomal AAV insertion system No long-term immune X ✓✓ suppression: Potential added non-viral advantages: Potential re-dosing: X ✓✓ • Technology overcomes critical limitations and stalled uptake Large
Slide 63: Poseida's non-viral system has potential to address unmet needs for Hemophilia A patients
Poseida’s non-viral system has potential to address unmet needs for Hemophilia A patients • Non-viral lipid nanoparticle (LNP) • Transposition in hepatocytes for delivery less immunogenic potential long-term durability • Greater access without concerns of • 13 months of FVIII expression with prior v
Slide 64: DNA insertion technology enables whole gene functional correction
DNA insertion technology enables whole gene functional correction Key advantages of our gene insertion approach over Cas9 knock-ins and episomal strategies Transposon function Transposon advantages Cas9 knock-in challenges 1 • Stability & durability (vs. episome) • Double-strand breaks 4 2 • No doub
Slide 65: Large cargo capacity transposon provides optimal FVIII levels and optionality
Large cargo capacity transposon provides optimal FVIII levels and optionality Transposon vector DNA Insulator FVIII Modulator switch Gene correction Modulate / off Durability Expression hFVIII Levels Modified 80 Cell 70 100 60 + Insulator 80 50 60 Switch 40 Activation 30 40 20 – Insulator 20 10 0 Ce
Slide 66: Next-gen DNA/mRNA drives efficient insertion for maximal FVIII expression
Next-gen DNA/mRNA drives efficient insertion for maximal FVIII expression Iterative engineering of both transposon and transposase yields key advantages for robust FVIII levels Transposon DNA Transposase mRNA 1000 1000 100 100 10 10 1 0.1 1 A B C D E A B C D E FVIII Transposon Version SPB mRNA Versi
Slide 67: Hemophilia A only requires minimal integration in small proportion of liver cells
Hemophilia A only requires minimal integration in small proportion of liver cells Key safety advantage with fewer vector copies per cell, for minimizing insertional mutagenesis Very low vector copy numbers 1-5 Rate Per Year: Human tissues 100,000 Sun-exposed 10,000 How much is needed for therapeutic
Slide 68: Poseida gene insertion technology has a favorable integration profile
Poseida gene insertion technology has a favorable integration profile No safety findings following extensive in vivo studies No transformation Favorable integration profile Tumor-prone Model 40 • No liver lesions associated with Gene/Non-Gene Sequence 1-4 5-7 8 Preference Preference transposition 30
Slide 69: Poseida non-viral system provides FVIII expression with low immunogenicity
Poseida non-viral system provides FVIII expression with low immunogenicity Key delivery technology provides high tolerability in mice without compromising FVIII expression ALT IL-6 Plasma FVIII 6000 250000 60 5000 50 200000 4000 40 150000 3000 30 100000 2000 20 50000 1000 10 0 0 0 Vehicle Conv. Vehi
Slide 70: Durable FVIII expression achieved in adult mouse model across 13 months
Normal Declining FVIII expression for episomal DNA Durable FVIII expression achieved in adult mouse model across 13 months Target levels achieved throughout study, providing key markers for success Clotting efficacy FVIII expression in adult Hemophilia A mice 13 months 40 with DNA insertion 100 50 P
Slide 71: Titrating to efficacy via repeat dosing achieved in multiple studies
Titrating to efficacy via repeat dosing achieved in multiple studies Additional repeat dosing experiments highlight ability to provide a rescue dose FVIII rescue in adult hemophilia A mice FVIII activity in adult hemophilia A mice 150 150 hFVIII DNA + Cat. Dead SPB 125 100 hFVIII DNA only 125 75 hFV
Slide 72: Performance in growing liver supports principle of early intervention
Performance in growing liver supports principle of early intervention Advantage for pediatrics hFVIII expression in neonatal mice 1000 800 Insertion = levels maintained 600 DNA integration 400 Durable FVIII production and expression 200 20 15 10 Complete loss w/o integration (episomal) Liver Growth
Slide 73: New options enabled to down-regulate / remove expression
New options enabled to down-regulate / remove expression Large cargo capacity with our non-viral system enables added optionality Proof of concept results Off/Modulator Switch 1000 • Capable of “dialing down” FVIII levels • Very small minority of hepatocytes impacted 100 • Provides option to switch
Slide 74: Validation across multiple species, progress towards clinical readiness
Validation across multiple species, progress towards clinical readiness • Continued thought-leader engagement Clinical • Rapid clinical feasibility • Early planning for process & analytical dev, and manufacturing CMC Regulatory • Preparing early engagement discussion materials Mice Rats ✓ Proof of p
Slide 75: Site-Specific Super piggyBac (ssSPB) Advancements
Site-Specific Super piggyBac (ssSPB) Advancements Up d ate on site -specific ge n e in sertion ap p roach P r e s e n t e r : B l a i r M a d i s o n , P h D 75
Slide 76: Unlocking the ideal traits of site-specific gene insertion with site specific SPB
Unlocking the ideal traits of site-specific gene insertion with site specific SPB • Reprogrammability • High-fidelity, yielding only desired edits • Whole gene integration • Efficient integration rates • Targeting any genomic region • Simplicity • Gene knock-out and knock-in • Promoterless approach
Slide 77: Site-specific SPB technology provides a simple system for targeted gene insertion
Site-specific SPB technology provides a simple system for targeted gene insertion Cas9 and nucleases: the wrong fit DNA Break 1 • Double-strand breaks Site-specific SPB 2 • DNA repair needed 3 • Unintended mutations 1-3 • Irreversible (one shot) Simple single enzyme fusion system ATGGACTG-INDEL-ATCG
Slide 78: Site-specific SPB executes each cut-find-paste step with a single enzyme fusion protein
Site-specific SPB executes each “cut-find-paste” step with a single enzyme fusion protein Site-specific “cut, find, paste” integration Site-specific SPB for additional control + DNA CARGO ITR ITR CUT • Excision from the donor vector/plasmid DNA FIND ITR DNA CARGO ITR • DNA-finding modules direct int
Slide 79: Early version of site-specific SPB yields in vivo targeted transposition in mouse liver
Early version of site-specific SPB yields in vivo targeted transposition in mouse liver In vivo site-specific integration 0.015 Site-specific integration toolkit 0.010 Transposase Target finding 0.005 DNA Donor 0.000 PBS PBx Site-Specific • In vivo site-specific integration of cargo detected in live
Slide 80: Further site-specific SPB engineering boosts on-target insertion rate
Further site-specific SPB engineering boosts on-target insertion rate at single-copy sites Points of optimization Integration at single copy target site DNA CARGO ITR ITR 1 Cas9 HDR Site-specific SPB DBD Linker ITR Transposase 8 7 6 Target Transposase Cargo Executes 5 Recognition Positioning Recogni
Slide 81: Site-specific SPB enables the targeting of repetitive sites
Site-specific SPB enables the targeting of repetitive sites, where nucleases would likely fail Targeting repeats Site specific CRISPR/ Breaching limit of single-copy target sites transposase nuclease Site-specific integration efficiencies 100 Repetitive DNA 10 1 Max of single-copy sites 1 0.1 Enhanc
Slide 82: Predictable and reproducible integration with >90% on target fidelity
Predictable and reproducible integration with >90% on target fidelity Efficiency data Fidelity data 3000 Repetitive DNA Targets Site 1 >90% on-target 6 Site 2 2000 4 2 1000 HepG2 0 cells HepG2 HEK293T HepG2 HEK293T 0 Entire Genome - Millions of Possible Integration Sites Site 1 Site 2 • Efficient, s
Slide 83: Site-specific SPB provides a foundational toolkit for targeted gene insertion
Site-specific SPB provides a foundational toolkit for targeted gene insertion Summary • Molecular evolution of site-specific SPB technology enhanced 30-fold over early generation • Site-specific SPB technology efficient for targeted cargo integration at single- and multi-copy sites • Validated benef
Slide 84: Conclusion
Conclusion P r e s e n t e r : K r i s t i n Ya r e m a , P h D 84
Slide 85: Peter Marks quote on accelerated approval and genome editing
“If we don’t lean into accelerated approval, we’re going to leave a lot of patients behind” “I think the possibility of genome editing… could be an incredible game changer, not just for rare diseases but more common disease.” – Peter Marks, Director of the Center for Biologics Evaluation and Researc
Slide 86: This is just the beginning…
This is just the beginning… Our powerful toolkit has the potential to unlock significant opportunities to address areas of unmet medical need Illustrative Gene editing Gene insertion opportunities Other rare or prevalent diseases (addressable by genetic medicines) In vivo In vivo CAR-T (oncology and
Slide 87: Poseida positioned to deliver on the promise of genetic medicines
With a broad suite of differentiated gene editing technologies, Poseida is positioned to deliver on the promise of genetic medicines Manufacture and delivery Whole gene insertion High fidelity gene editing DNA transposon RNA-guided DNA nuclease LNP We will continue to evaluate the right opportunity